On January 14, 2021 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that the Company will present at the NobleCon17, Noble Capital Markets’ Annual Investor Conference, taking place virtually January 19-20 (Press release, Genprex, JAN 14, 2021, View Source [SID1234574007]). Genprex’s President and Chief Executive Officer, Rodney Varner, will virtually deliver a company overview, including recent progress made on its upcoming clinical trials, to participating investors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Event: NobleCon17
Presentation Date: Tuesday, January 19
Presentation Time: 3:45 p.m. EST – Track 1
Registration Link: https://bit.ly/3oAVY1c
A high-definition, video webcast of the presentation will be available for replay on the Company’s website (www.genprex.com) for a period of time following the conference, and the replay will also be available as part of a complete catalog of presentations to be rebroadcast on Channelchek at www.channelchek.com next month.
Noble Capital Markets recently released a report on Channelchek, its small and microcap database titled, "The Most Studied Research, Most Popular Videos, and Most Read Articles of 2020." The report reviewed Channelchek’s most popular content from 2020, and found that a research note on Genprex took the number one spot for being the most read research report of the year.